Ignite Creation Date:
2024-05-06 @ 3:12 PM
Last Modification Date:
2024-10-26 @ 1:44 PM
Study NCT ID:
NCT04550975
Status:
UNKNOWN
Last Update Posted:
2020-09-16
First Post:
2020-09-01
Brief Title:
Advanced Cognitive Stimulation Therapy ACST
Sponsor:
University College London
Organization:
University College London
Study Overview
Official Title:
Feasibility Randomised Controlled Trial RCT of Advanced Cognitive Stimulation Therapy ACST for People With Moderate to Severe Dementia
Status:
UNKNOWN
Status Verified Date:
2020-09
Last Known Status:
NOT_YET_RECRUITING
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is a feasibility randomised controlled trial RCT for an evidence-based intervention for people with moderate to severe dementia The psychosocial intervention is adapted from Cognitive Stimulation Therapy CST and developed within the Medical Research Council MRC framework
Detailed Description:
The World Health Organization calls for an increase of psychosocial interventions for dementia-a global epidemic Cognitive Stimulation Therapy CST is the only non-pharmacological therapy recommended by the National Institute for Health and Care Excellence for improving cognition for mild to moderate dementia However there is little guidance on how to maximise cognition for severe dementia Advanced Cognitive Stimulation Therapy ACST will be the first evidence-based complex intervention for moderate to severe dementia developed within the Medical Research Council MRC framework and building upon CSTs key principles This feasibility randomised controlled trial RCT aims to 1 evaluate the feasibility of ACST 2 explore if ACST can improve the cognitive function and QoL as well as other outcomes including behaviour engagement and communication for people with moderate to severe dementia A sample of 32 participants will be recruited where 16 will be randomly allocated to ACST and 16 to treatment as usual TAU Data will be collected pre and post the 7-week intervention period Improving cognition and QoL for people with moderate to severe dementia is vital because dementias prevalence is projected to reach 152 million by 2050 resulting in excessive excess disability
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None